Claudia L. Seguin

Claudia L. Seguin

Auto-generated profile, based on publicly available information

Claudia L. Seguin

Institute for Technology Assessment, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in JCO Oncology Practice
Verified
Journal Article
Closed access
MPMary Linton B Peters
Mary Linton B Peters
AEAndrew Eckel
Andrew Eckel
CSClaudia L. Seguin
Claudia L. Seguin
BDBarak Davidi
Barak Davidi
DHDavid H. Howard
David H. Howard
PPPari V. Pandharipande
Pari V. Pandharipande
PURPOSE: We evaluated the potential cost-effectiveness of combined magnetic resonance imaging (MRI) and endoscopic ultrasound (EUS) screening for pancreatic ductal adenocarcinoma (PDAC) among populations at high risk for the disease. METHODS: We used a microsimulation model of the natural history of PDAC to estimate the lifetime health benefits, costs, and cost-effectiveness of PDAC screening among populations with specific genetic risk factors for PDAC, including BRCA1 and BRCA2, PALB2, ATM, Lynch syndrome, TP53, CDKN2A, and STK11. For each high-risk population, we simulated 29 screening strategies, defined by starting age and frequency. Screening included MRI with follow-up EUS in a subset of patients. Costs of tests were based on Medicare reimbursement for MRI, EUS, fine-needle aspiration biopsy, and pancreatectomy. Cancer-related cost by stage of disease and phase of treatment was based on the literature. For each high-risk population, we performed an incremental cost-effectiveness analysis, assuming a willingness-to-pay (WTP) threshold of $100,000 US dollars (USD) per quality-adjusted life year (QALY) gained. RESULTS: For men with relative risk (RR) 12.33 ( CDKN2A) and RR 28 ( STK11), annual screening was cost-effective, starting at age 55 and 40 years, respectively. For women, screening was only cost-effective for those with RR 28 ( STK11), with annual screening starting at age 45 years. CONCLUSION: Combined MRI/EUS screening may be a cost-effective approach for the highest-risk populations (among mutations considered, those with RR >12). However, for those with moderate risk (RR, 5-12), screening would only be cost-effective at higher WTP thresholds (eg, $200K USD/QALY) or with once-only screening.

3 July 2023 in Journal of the American College of Radiology
Verified
Journal Article
Closed access
CSClaudia L. Seguin
Claudia L. Seguin
BDBarak Davidi
Barak Davidi
MPMary Linton B. Peters
Mary Linton B. Peters
AEAndrew Eckel
Andrew Eckel
MHMukesh G. Harisinghani
Mukesh G. Harisinghani
PPPari V. Pandharipande
Pari V. Pandharipande

31 May 2022 in Pancreatology
Verified
Journal Article
Closed access
MPMary Linton B Peters
Mary Linton B Peters
AEAndrew Eckel
Andrew Eckel
ALAnna Lietz
Anna Lietz
CSClaudia Seguin
Claudia Seguin
PMPeter Mueller
Peter Mueller
PPPari V. Pandharipande
Pari V. Pandharipande

1 February 2026 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JYJennifer M. Yeh
Jennifer M. Yeh
CSClaudia L. Seguin
Claudia L. Seguin
KSKayla L. Stratton
Kayla L. Stratton
WLWendy M. Leisenring
Wendy M. Leisenring
GAGregory T. Armstrong
Gregory T. Armstrong
AKAmy B. Knudsen
Amy B. Knudsen
PURPOSE: Childhood cancer survivors treated with abdominopelvic radiation (RT) are at increased risk of colorectal cancer (CRC), yet adherence to Children's Oncology Group screening guidelines remains low. Estimating the benefits, burdens, and costs of all guideline-recommended screening modalities, including those not previously evaluated, may help identify strategies that align with survivors' preferences and access, potentially improving adherence. METHODS: Using data from the Childhood Cancer Survivor Study and published studies, we adapted a CRC simulation model to evaluate CRC screening among 5-year survivors. Strategies included colonoscopy, multitarget stool DNA (mtsDNA), and fecal immunochemical testing (FIT) at various intervals, starting at age 25-45 years. Outcomes included CRC cases and deaths, additional colonoscopies per additional life-year gained (burden-to-benefit ratio [BBR]), and cost per quality-adjusted life-year gained (QALYG; incremental cost-effectiveness ratios [ICERs]). RESULTS: At age 45 years, survivors had a 0.6% cumulative CRC risk (relative risk, 3.3 v average-risk individuals). Without screening, an estimated 75 per 1,000 survivors would be diagnosed with CRC in their lifetime and 30 would die from CRC. Screening averted 47-73 cases and 23-29 CRC deaths per 1,000. Based on average-risk BBR benchmarks, the optimal strategies by modality were colonoscopy every 10 years starting at age 30 years, mtsDNA every 3 years starting at age 30 years, and FIT every 3 years starting at age 25 years (then annually as of age 45 years, as recommended for average-risk individuals). ICERs were $146,000 in US dollars (USD)/QALYG, $166,000 (USD)/QALYG, and $123,000 (USD)/QALYG, respectively. CONCLUSION: Early initiation of screening with colonoscopy or stool-based tests may substantially reduce CRC incidence and early mortality among survivors treated with abdominopelvic RT, with reasonable burden-to-benefit trade-offs, and be considered cost-effective. These findings can facilitate clinician-survivor discussions on CRC screening and inform guideline refinements.

1 March 2023 in medRxiv
Verified
Preprint
Open access
PDF file
CACarlos Pineda Antunez
Carlos Pineda Antunez
CSClaudia Seguin
Claudia Seguin
LDLuuk A van Duuren
Luuk A van Duuren
AKAmy B. Knudsen
Amy B. Knudsen
BDBarak Davidi
Barak Davidi
FAFernando Alarid-Escudero
Fernando Alarid-Escudero
Purpose To calibrate Cancer Intervention and Surveillance Modeling Network (CISNET) ‘s SimCRC, MISCAN-Colon, and CRC-SPIN simulation models of the natural history colorectal cancer (CRC) with an emulator-based Bayesian algorithm and internally validate the model-predicted outcomes to calibration targets. Methods We used Latin hypercube sampling to sample up to 50,000 parameter sets for each CISNET-CRC model and generated the corresponding outputs. We trained multilayer perceptron artificial neural networks (ANN) as emulators using the input and output samples for each CISNET-CRC model. We selected ANN structures with corresponding hyperparameters (i.e., number of hidden layers, nodes, activation functions, epochs, and optimizer) that minimize the predicted mean square error on the validation sample. We implemented the ANN emulators in a probabilistic programming language and calibrated the input parameters with Hamiltonian Monte Carlo-based algorithms to obtain the joint posterior distributions of the CISNET-CRC models’ parameters. We internally validated each calibrated emulator by comparing the model-predicted posterior outputs against the calibration targets. Results The optimal ANN for SimCRC had four hidden layers and 360 hidden nodes, MISCAN-Colon had 4 hidden layers and 114 hidden nodes, and CRC-SPIN had one hidden layer and 140 hidden nodes. The total time for training and calibrating the emulators was 7.3, 4.0, and 0.66 hours for SimCRC, MISCAN-Colon, and CRC-SPIN, respectively. The mean of the model-predicted outputs fell within the 95% confidence intervals of the calibration targets in 98 of 110 for SimCRC, 65 of 93 for MISCAN, and 31 of 41 targets for CRC-SPIN. Conclusions Using ANN emulators is a practical solution to reduce the computational burden and complexity for Bayesian calibration of individual-level simulation models used for policy analysis, like the CISNET CRC models.

16 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
CSClaudia L. Seguin
Claudia L. Seguin
AEAndrew Eckel
Andrew Eckel
CWClare E. Wiberg
Clare E. Wiberg
LCLing Chen
Ling Chen
JAJoel Agarwal
Joel Agarwal
PPPari V. Pandharipande
Pari V. Pandharipande
Objective: Maintenance therapy with poly(ADP-ribose) polymerase inhibitors (PARPi) improves survival in patients with advanced epithelial ovarian cancer (EOC), a benefit most pronounced in patients with homologous recombination deficient (HRD) tumors. We estimated the survival benefits of increasing universal germline and somatic testing among patients with advanced EOC. Methods: We developed a simulation model to estimate the survival of patients with newly diagnosed stage III or IV EOC, using data from the National Cancer Database (NCDB). In our model, we applied hazard ratios from clinical trials to survival data from the NCDB, in order to reflect the differential effects of maintenance PARPi in patients who are germline BRCA1/2+; somatic BRCA1/2+ (or other HRD mutation+); or homologous recombination proficient (HRP). We simulated a "current practice" strategy, in which only half of patients received HRD testing, and a "universal testing" strategy, in which all patients were tested. In the primary analysis, we compared the predicted median survival. In sensitivity analyses, we explored effects of 100% uptake of PARPi among eligible patients. Results: In the “current practice” strategy, median survival was 49 months. With “universal testing”, median survival increased to 51 months, a 2-month benefit compared to current practice. In a sensitivity analysis, the median survival associated with universal testing and 100% uptake of PARPi was 53 months, a 4-month benefit compared to “current practice.” Conclusions: Universal HRD testing may improve median survival by 2 months for patients diagnosed with advanced EOC. Increased PARPi uptake may extend this benefit by an additional 2 months.